Lilly’s weight-loss medications Mounjaro and Zepbound are gaining market share on Novo’s Wegovy and Ozempic, but investors remain unconvinced.
It’s been a week of wins for Eli Lilly’s weight-loss drugs. In the company’s second quarter earnings report on Thursday, it reported that sales of Mounjaro, its type-2 diabetes medication often used for weight loss, reached nearly $5.2 billion in revenue, up 68% from the same quarter last year and exceeding analyst estimates of $4.7 billion. Similarly, its weight-loss medication Zepbound reached $3.4 billion in sales, up 172% year-over-year and exceeding estimates of $3 billion.
